To determine the efficacy of antiplatelet therapy in maintaining vascular patency in various categories of patients.
Studies were reviewed by the collaborative review group. Individual data were requested from investigators to judge patient recruitment and eligibility, duration of treatment and the classification of outcomes
Assessment of study quality
Trials had to demonstrate they used concealed treatment allocation (randomisation method precluded prior knowledge of the next treatment), and were unconfounded (one treatment group differed from the other only in the treatment of interest). Trials were required to use the same method for assessing patency in both treatment and control groups. Information about the exact nature of randomisation, treatment allocation, placebos, and blinding procedures was requested from individual investigators and assessed by the collaborative review group.
Data extraction
Summary data for each study were requested from principal investigators for each trial, and checked for internal consistency and with published reports of the trials. Individual patient data were requested and intention to treat analyses were performed for most studies. When the data were not available, the study was included unless the number of exclusions was so extensive that the trial could not be considered properly randomised.
There was no evidence of differences between antiplatelet agents and regimens, or from indirect comparisons, according to when the antiplatelet treatment was commenced.
Authors' conclusions
Antiplatelet therapy (chiefly aspirin alone, or aspirin plus dipyridamole) greatly reduces the risk of vascular occlusion in a wide range of patients at high risk of this complication. Further studies are required to determine exactly when treatment should start (to limit any perioperative bleeding while still preventing most early occlusion) and for how long it should be continued.
CRD commentary
The Antiplatelet Trialists' Collaboration employed rigorous review methods, including the pursuit of individual patient data and thorough checking of individual study results, which ensure that the results of the review are valid. Recommendations on using the treatment rely on the benefits of reduced occlusion rates outweighing the risks of major bleeds. Whilst the data on haemorrhages is incomplete, the difference in rates and the note that most bleeds were nonfatal, suggests that the conclusions are robust. In some of the included trials, the outcome assessment was not performed blind which is a potential threat to validity. However, comparison with the results of a synthesis limited to only placebo-controlled trials, which are more likely to have had blind outcome assessment, suggests that the results are not materially affected by this potential bias.
Implications of the review for practice and research
Antiplatelet therapy should be considered for patients undergoing coronary artery bypass grafting or angioplasty, or leg artery bypass grafting or angioplasty, and for those with fistulas or shunts placed for haemodialysis access, unless there are contraindications. The timing of commencement of therapy and duration of therapy should be investigated in further randomised controlled trials.
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